News and Comments

NANTKWEST INC. A Novel Breathtaking Immunotherapy For Cancer?

  Monday, August 03, 2015

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some called it the “New Golden Boy”. During the IPO, investors who knew about this firm and were waiting for that day seemed confident that the stock would surge. As a matter of fact, the stock did surge.    More...

EXELEXIS: The Importance Of The Public Offering. XOMA: What Should We Do Now?

  Thursday, July 23, 2015

Why the financing through a secondary public offering was a must for Exelixis?  More...

AMGN: Rapatha Approved In Europe

  Tuesday, July 21, 2015

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol More...

Anacor Pharmaceuticals Ointment for Atopic Dermatitis Passes the Tests. Why is this Great News?

  Tuesday, July 14, 2015

An Effective Non-Steroid Atopic Dermatitis Ointment More...

Trovagine: Overcoming Challenges In Cancer Immunotherapy

  Wednesday, July 08, 2015

After decades of attempting, but failing, to harness the immune system power to treat cancer (Cancer immunotherapy), novel approaches based on new discoveries have finally demonstrated they can do the hard job. These treatments, however, are facing challenges, which must be dealt with. Will Trovagine (TROV) succeed in dealing with the challenges?  More...

Unearthing Dynavax Treasures has Nothing To Do with Greece Troubles

  Monday, June 29, 2015


Biocryst: A Major Game Changing Agreement

  Monday, June 22, 2015

On Thursday June 18, we posted an article in “Today’s Highlights” section in the Prohost Website about an important agreement Biocryst Pharmaceuticals (BCRX) signed with CSL We expect the agreement to contribute a great deal into bringing effective treatments of disabling chronic progressive diseases and life-threatening acute diseases to the global market   More...

Immunogen: Defeating Advanced Ovarian Cancer And Other Malignancies

  Tuesday, June 02, 2015

- Immunogen’s recurrent ovarian cancer drug Mirvetuximab soravtansine (IMGN853) has demonstrated promising results. More...

Xoma: Phase 3 EYEGUARD-B Trial is Good News For Gevokizumab

  Wednesday, May 27, 2015

Xoma (XOMA) announced good news from Phase 3 EYEGUARD-B trial of its monoclonal antibody drug gevokizumab for Behcet’s uveitis. The study, which is sponsored by Xoma’s development partner Servier, reached its target exacerbation event as specified in the study design.  More...


  Friday, May 22, 2015

For those who ask whether immunotherapy will have a dominant presence at ASCO, we confirm that yes; immunotherapy therapeutics will have a presence and a lot of audience, especially oncologists. There is big reason for oncologists’ interest in the subject. Their patients who have exhausted all standard of care treatments and would usually go home to die, did not lose hope this time. Instead, many embarked on investigational immunotherapy clinical trials. The two categories that dominate immunotherapy are immune checkpoint protein inhibitors and CAR T cell therapeutics. Both will be presented and we will be all ears to hear.  More...

Recent Postings



VANDA (VNDA) NEKTAR (NKTR)) AstraZeneca (AZN) ABBVIE (ABBV) Amgen (AMGN) Ziofpharm (ZIOP) ARGOS (ARGS) Prolor Biotech (PBTH) JUNO (JUNO) Cytokinetics (CYTK) Prosensa (RNA) PTC Therapeutics (PTCT) C4 Therapeutics PORTOLA (PTLA) Exelixis (EXEL) Global Cell Therapeutics (GBT) AGOS (ARGS) ISIS (ISIS) Aimmune Therapeutics (AIMT) Benlysta (belimumab) Roche (ROCHE) IDERA (IDRA) Bellicum (BLCM) Galena (GALE) Human Longevity (HLI) Dendreon (DNDN) SUNESIS PHARMACEUTICALS (SNSS) Multiple Myeloma Illumina (ILMN) Elan (ELN) Telaprevir Bristol-Myers Squibb (BMY) Alnylam (ALNY) galapagos (GLPG) Inovio (INO) Advaxis (ADXS) Dynavax (DVAX) Herceptin ImmunoGen (IMGN) KERYX (KERX) Ridaforolimus Idenix (IDIX) Biogen Idec (BIIB) ARCA (ABIO) Intercept (ICPT) Sanofi (SNA) Revlimid (lenolidamide) Ionis (IONS) SYNTA (SNTA) Jazz Pharmaceuticals (JAZZ) Anadys (ANDS) Rapamune SERES THERAPEUTICS (MCRB) Gilead (GILD) Ocular Therapeutix (OCUL) Auspex (ASPX) Ariad (ARIA) ACADIA (ACAD) GUARDIAN HEALTH NOVOCURE (NVCR) GlaxoSmithKline (GSK) Micromet (MITI) Incyte (INCY) Array Pharmaceuticals (ARRY) Sanofi-Aventis (SAN) MODERNA Spike Therapeutics (ONCE) REGULUS (RGLS) Vitae Pharmaceuticals (VTAE) AERIE PHARMACEUTICALS ADVENTRIX (ANX) INNOVIVA (INVA) ZALTRAP™ Agenus (AGEN) CRISPR Therapeutics (CRSP) Intrexon (XON) Genentech Zerenex KITE (KITE) Agenus (AGEN Regeneron (REGN) TOKAI (TKAOI) Vertex (VRTX) OSI (OSIP) Sangamo (SGMO) Theravance Bio Pharma (TBPH) CEMPRA (CEMP) Velcade (bortezomib) Valeant Pharmaceuticals International (VRX) CompuGen (CGEN) Mirati Therapeutics (MRTX) Anacor (ANAC) Theravance (THRX) Trastuzumab-DM1 NANTKWEST (NK) Adaptimmune (ADAP) Abbott Laboratories (ABT) Intermune (ITMN) Pluristem (PSTI) Xoma (XOMA) RenenxBio (RGNX) Onyx (ONXX) Tysabri Sequenom (SQNM) Editas (EDIT) Roche (RHHBY) HALOZYME (HALO) Biocryst (BCRX) Endometrial Cancer Sarepta (SRPT) Sanofi (SNY) BIOMARIN (BMRN) Seattle Genetics (SGEN) Merck (MRK) Human Genome Sciences (HGSI) Alder Biopharmaceuticals (ALDR)